Below you'll find a list of all posts that have been categorized as “Kelso Pharma”
ALTURiX, part of the Kelso Pharma Group, will be presenting new research at the International League Against Epilepsy (ILAE) British Branch Annual Scientific Conference, beginning tomorrow (8th October 2026), highlighting the significant challenges faced by people living with epilepsy and healthcare professionals when managing rescue medications.
Kelso Pharma, the high-growth specialty pharmaceuticals business, announces that Italian-based Velit Biopharma, acquired in November 2023, will trade as ‘Kelso Pharma Italy’ from today (21 October 2025), as the business gears up for further growth across European markets.
Kelso Pharma, the high-growth specialty pharmaceuticals business, announces that Allan Watson, the company’s Chief Financial Officer, has decided to retire from his role and is being succeeded by life sciences financial specialist, Alan King.
Kelso Pharma, the growing UK-based specialty pharmaceuticals business, has appointed life sciences leader, Dr. Bee Koen Low, as its first Chief Operating Officer.
Kelso Pharma, the growing specialty pharma business backed by Apposite Capital, the healthcare specialist private equity investor, announces that it has secured over £140 million of acquisition funding and appointed former ADVANZ PHARMA CEO, Graeme Duncan, as Non-Executive Director.
Kelso Pharma, the growing specialty pharma business backed by Apposite Capital, the healthcare specialist private equity investor, today (19 February 2025) announces the acquisition of the UK pharma business, ALTURiX Holdings Limited (ALTURiX).
Kelso Pharma, the growing UK based specialty pharmaceuticals business, has appointed experienced pharma executive, John Rooper, as Director of Corporate Development as the company eyes further growth across international markets.
The acquisition of Italian specialty pharma company, Velit Biopharma (Velit), by UK-based specialty pharma business, Kelso Pharma (Kelso), announced on 13th November 2023, has now closed.
Kelso Pharma, the growing UK-based specialty pharma business, has concluded two new collaboration agreements with pharmaceuticals companies, PharmaPath and Valpharma.
Kelso Pharma (Kelso), the growing UK-based specialty pharma business, has taken its first step in its European expansion strategy by agreeing to acquire Italian specialty pharma company, Velit Biopharma (Velit).
Kelso Pharma, the growing UK-based specialty pharma business, has concluded a deal to acquire two UK approved products, representing an exciting launch into the specialty of Dermatology with prescription medicines for the treatment of actinic keratoses and plaque psoriasis.
Kelso Pharma, the growing UK based specialty pharma business, has announced its first product launch with the release to the UK prescription medicines market of Acepiro® (Acetylcysteine) 600mg effervescent tablets.
Spreng Thomson: Intelligent Creative Communications
Spreng Thomson is committed to Fair Work, by ensuring that our people have an effective voice, by investing in their development and by not using zero hours contracts.
+44(0)141 548 5191
[email protected]
The Herald Building,
155 Albion Street,
Glasgow G1 1RU, UK
© 2026 Spreng Thomson Limited.
Registered in Scotland No. 173454
